2019

1. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

   British Journal of Haematology, Vol. 187, Núm. 1, pp. 93-104

2. Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology

   International Journal of Laboratory Hematology, Vol. 41, Núm. 1, pp. 109-117